The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase IIb, open-label, single-arm study of zanidatamab (ZW25) monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers.
 
Shubham Pant
Honoraria - 4D Pharma
Consulting or Advisory Role - TYME; Xencor; Zymeworks
Research Funding - ArQule (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Five Prime Therapeutics (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Onco Response (Inst); RedHill Biopharma (Inst); Rgenix (Inst); Sanofi/Aventis (Inst); Xencor (Inst)
 
Michel Ducreux
Employment - Sandoz (I)
Honoraria - Amgen; Bayer; Celgene; Ipsen; Lilly; Merck Serono; MSD Oncology; Novartis; Roche/Genentech; Servier
Consulting or Advisory Role - Amgen; Celgene; HalioDx; Ipsen; Lilly; Merck Serono; Novartis; Pierre Fabre; Roche; Servier
Speakers' Bureau - Bayer; Celgene; Ipsen; Merck KGaA; Roche
Research Funding - Keocyt (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Ipsen; Merck Serono; Roche
 
James J. Harding
Consulting or Advisory Role - Adaptimmune; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; Exelixis; Imvax; Lilly; Merck; Zymeworks
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Debiopharm Group (Inst); Incyte (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Polaris (Inst); Yiviva (Inst); Zymeworks (Inst)
 
Milind M. Javle
Consulting or Advisory Role - AstraZeneca; EMD Serono; incyte; Merck; Mundipharma; oncosil; QED Therapeutics
Other Relationship - Bayer; BeiGene; Incyte; Merck; Merck Serono; Novartis; Pieris Pharmaceuticals; QED Therapeutics; Rafael Pharmaceuticals; Seagen
 
Do-Youn Oh
Consulting or Advisory Role - ASLAN Pharmaceuticals; AstraZeneca; Bayer; Celgene; Genentech/Roche; Halozyme; Merck Serono; Novartis; Taiho Pharmaceutical; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; Lilly; Novartis
 
Harpreet Singh Wasan
Honoraria - Array BioPharma; Celgene; ERYTECH Pharma; Incyte; Merck KGaA; Roche/Genentech; Servier; Sirtex Medical; Zymeworks
Consulting or Advisory Role - Bayer; ERYTECH Pharma; Incyte; Pfizer; Pierre Fabre; Roche Pharma AG; Shire; Sirtex medical
Speakers' Bureau - Celgene; Incyte; Merck KGaA; SERVIER; Sirtex Medical
Research Funding - Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Sirtex Medical (Inst)
 
Allison Fortenberry
Employment - Zymeworks
Stock and Other Ownership Interests - Zymeworks
Travel, Accommodations, Expenses - Zymeworks
 
Neil C. Josephson
Employment - Seagen; Zymeworks
Stock and Other Ownership Interests - Seagen; Zymeworks
 
Anthony Mwatha
Employment - Zymeworks
Stock and Other Ownership Interests - Zymeworks
Travel, Accommodations, Expenses - Zymeworks
 
Kui Wang
Employment - BeiGene
 
Jia Fan
No Relationships to Disclose